AAAAAA
Results: 1-25/53
Authors:
HANSEN LL
LARSEN JT
BROSEN K
Citation: Ll. Hansen et al., DETERMINATION OF TACRINE AND ITS METABOLITES IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE DETECTION, Journal of chromatography B. Biomedical sciences and applications, 712(1-2), 1998, pp. 183-191
Authors:
BATHUM L
JOHANSSON I
INGELMANSUNDBERG M
HORDER M
BROSEN K
Citation: L. Bathum et al., ULTRARAPID METABOLISM OF SPARTEINE - FREQUENCY OF ALLELES WITH DUPLICATED CYP2D6 GENES IN A DANISH POPULATION AS DETERMINED BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND LONG POLYMERASE-CHAIN-REACTION, Pharmacogenetics, 8(2), 1998, pp. 119-123
Authors:
FJORDSIDE L
JEPPESEN U
EAP CP
POWELL K
BAUMANN P
BROSEN K
Citation: L. Fjordside et al., THE STEREOSELECTIVE METABOLISM OF FLUOXETINE IN POOR AND EXTENSIVE METABOLIZERS OF SPARTEINE, Nordic journal of psychiatry, 52(2), 1998, pp. 113-114
Authors:
LARSEN JT
HANSEN LL
BROSEN K
Citation: Jt. Larsen et al., TACRINE-FLUVOXAMINE INTERACTION STUDY IN HEALTHY-VOLUNTEERS, Nordic journal of psychiatry, 52(2), 1998, pp. 122-122
Authors:
BROSEN K
Citation: K. Brosen, DIFFERENCES IN INTERACTIONS OF SSRIS, International clinical psychopharmacology, 13, 1998, pp. 45-47
Authors:
BATHUM L
HANSEN TS
HORDER M
BROSEN K
Citation: L. Bathum et al., A DUAL-LABEL OLIGONUCLEOTIDE LIGATION ASSAY FOR DETECTION OF THE CYP2C19-ASTERISK-1, CYP2C19-ASTERISK-2, AND CYP2C19-ASTERISK-3 ALLELES INVOLVING TIME-RESOLVED FLUOROMETRY, Therapeutic drug monitoring, 20(1), 1998, pp. 1-6
Authors:
POULSEN L
RIISHEDE L
BROSEN K
CLEMENSEN S
SINDRUP SH
Citation: L. Poulsen et al., CODEINE IN POSTOPERATIVE PAIN - STUDY OF THE INFLUENCE OF SPARTEINE PHENOTYPE AND SERUM CONCENTRATIONS OF MORPHINE AND MORPHINE-6-GLUCURONIDE, European Journal of Clinical Pharmacology, 54(6), 1998, pp. 451-454
Authors:
BATHUM L
ANDERSENRANBERG K
BOLDSEN J
BROSEN K
JEUNE B
Citation: L. Bathum et al., GENOTYPES FOR THE CYTOCHROME-P450 ENZYMES CYP2D6 AND CYP2C19 IN HUMANLONGEVITY - ROLE OF CYP2D6 AND CYP2C19 IN LONGEVITY, European Journal of Clinical Pharmacology, 54(5), 1998, pp. 427-430
Authors:
BELPAIRE FM
WIJNANT P
TEMMERMAN A
RASMUSSEN BB
BROSEN K
Citation: Fm. Belpaire et al., THE OXIDATIVE-METABOLISM OF METOPROLOL IN HUMAN LIVER-MICROSOMES - INHIBITION BY THE SELECTIVE SEROTONIN REUPTAKE INHIBITORS, European Journal of Clinical Pharmacology, 54(3), 1998, pp. 261-264
Authors:
RASMUSSEN BB
BROSEN K
Citation: Bb. Rasmussen et K. Brosen, THEOPHYLLINE HAS NO ADVANTAGES OVER CAFFEINE AS A PUTATIVE MODEL-DRUGFOR ASSESSING CYP1A2 ACTIVITY IN HUMANS (VOL 43, PG 253, 1997), British journal of clinical pharmacology, 44(3), 1997, pp. 2-2
Authors:
RASMUSSEN BB
BROSEN K
Citation: Bb. Rasmussen et K. Brosen, THEOPHYLLINE HAS NO ADVANTAGES OVER CAFFEINE AS A PUTATIVE MODEL-DRUGFOR ASSESSING CYP1A2 ACTIVITY IN HUMANS, British journal of clinical pharmacology, 43(3), 1997, pp. 253-258
Authors:
RASMUSSEN BB
JEPPESEN U
GAIST D
BROSEN K
Citation: Bb. Rasmussen et al., GRISEOFULVIN AND FLUVOXAMINE INTERACTIONS WITH THE METABOLISM OF THEOPHYLLINE, Therapeutic drug monitoring, 19(1), 1997, pp. 56-62
Authors:
MADSEN H
RASMUSSEN JM
BROSEN K
Citation: H. Madsen et al., IS THERE INTERACTION BETWEEN TRAMADOL AND PHENPROCOUMON - REPLY, Lancet, 350(9090), 1997, pp. 1552-1553
Authors:
MADSEN H
RASMUSSEN JM
BROSEN K
Citation: H. Madsen et al., INTERACTION BETWEEN TRAMADOL AND PHENPROCOUMON, Lancet, 350(9078), 1997, pp. 637-637
Authors:
JEPPESEN U
RASMUSSEN JM
BROSEN K
Citation: U. Jeppesen et al., CLINICALLY IMPORTANT INTERACTION BETWEEN AZATHIOPRINE (IMUREL) AND PHENPROCOUMON (MARCOUMAR), European Journal of Clinical Pharmacology, 52(6), 1997, pp. 503-504
Authors:
CHRISTENSEN PM
GOTZSCHE PC
BROSEN K
Citation: Pm. Christensen et al., THE SPARTEINE DEBRISOQUINE (CYP2D6) OXIDATION POLYMORPHISM AND THE RISK OF LUNG-CANCER - A METAANALYSIS/, European Journal of Clinical Pharmacology, 51(5), 1997, pp. 389-393
Authors:
JEPPESEN U
RASMUSSEN BB
BROSEN K
Citation: U. Jeppesen et al., FLUVOXAMINE INHIBITS THE CYP2C19-CATALYZED BIOACTIVATION OF CHLOROGUANIDE, Clinical pharmacology and therapeutics, 62(3), 1997, pp. 279-286
Authors:
MADSEN H
RASMUSSEN BB
BROSEN K
Citation: H. Madsen et al., IMIPRAMINE DEMETHYLATION IN-VIVO - IMPACT OF CYP1A2, CYP2C19, AND CYP3A4, Clinical pharmacology and therapeutics, 61(3), 1997, pp. 319-324
Authors:
RASMUSSEN BB
BROSEN K
Citation: Bb. Rasmussen et K. Brosen, DETERMINATION OF THEOPHYLLINE AND ITS METABOLITES IN HUMAN URINE AND PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography B. Biomedical applications, 676(1), 1996, pp. 169-174
Authors:
MADSEN H
HANSEN TS
BROSEN K
Citation: H. Madsen et al., IMIPRAMINE METABOLISM IN RELATION TO THE SPARTEINE OXIDATION POLYMORPHISM - A FAMILY STUDY, Pharmacogenetics, 6(6), 1996, pp. 513-519
Authors:
JEPPESEN U
LOFT S
POULSEN HE
BROSEN K
Citation: U. Jeppesen et al., A FLUVOXAMINE-CAFFEINE INTERACTION STUDY, Pharmacogenetics, 6(3), 1996, pp. 213-222
Authors:
BROSEN K
Citation: K. Brosen, ARE PHARMACOKINETIC DRUG-INTERACTIONS WITH THE SSRIS AN ISSUE, International clinical psychopharmacology, 11, 1996, pp. 23-27
Authors:
BROSEN K
Citation: K. Brosen, DRUG-METABOLIZING-ENZYMES AND THERAPEUTIC DRUG-MONITORING IN PSYCHIATRY, Therapeutic drug monitoring, 18(4), 1996, pp. 393-396
Authors:
RASMUSSEN BB
BROSEN K
Citation: Bb. Rasmussen et K. Brosen, DETERMINATION OF URINARY METABOLITES OF CAFFEINE FOR THE ASSESSMENT OF CYTOCHROME P4501A2, XANTHINE-OXIDASE, AND N-ACETYLTRANSFERASE ACTIVITY IN HUMANS, Therapeutic drug monitoring, 18(3), 1996, pp. 254-262
Authors:
POULSEN L
BROSEN K
ARENDTNIELSEN L
GRAM LF
ELBAEK K
SINDRUP SH
Citation: L. Poulsen et al., CODEINE AND MORPHINE IN EXTENSIVE AND POOR METABOLIZERS OF SPARTEINE - PHARMACOKINETICS, ANALGESIC EFFECT AND SIDE-EFFECTS, European Journal of Clinical Pharmacology, 51(3-4), 1996, pp. 289-295